Regenerex Pharma discloses delinquent Q1/Q2 2026 10-Qs; 10-K filed late

REGENEREX PHARMA, INC.

2025 Form 10-K filed after deadline; Q1 and Q2 2026 10-Qs not yet filed and delinquent.
Company did not file Form 12b-25 notifications for the outstanding quarterly reports.
Delay attributed to additional accounting, reconciliation, and review work related to 10-K and quarterly statements.
Management working to complete and file outstanding reports as soon as practicable; no expected change to operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.